Strong growth from Vyepti® and focused commercial execution drive total revenue growth of +16% CER (+13% CER underlying) in H1 2026

Contributed by: PR Newswire

Tags

LUNDBECK-H1-26

More Like This

Lundbeck delivers 14% CER revenue growth, reflecting stronger momentum from Vyepti® and Rexulti® driven by additional investments

Takeda Announces Strong First Half FY2024 Results and Raises Full Year Outlook

Takeda Announces First-Quarter FY2025 Results With Significant Late-Stage Pipeline Progression

Takeda Reports Third-Quarter FY2025 Results: Updates Full Year Outlook to Reflect VYVANSE® Generics Impact, OPEX Discipline and FX Tailwind; Progressing Toward Three Transformative Launches Ahead

Sobi Q3 2024 report: Strong growth and significant pipeline momentum

Sobi Q2 2024 report: Strong delivery driven by robust portfolio performance

Takeda Announces First Quarter FY2024 Results - Strong Performance by Growth & Launch Products; Advancements in Promising Late-Stage Pipeline

Sobi Q1 2024 report: Strong sales reflecting the strength of the portfolio